One-Year Outcomes of Short-Term Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention With Drug-Eluting Stents: A Meta-Analysis of Randomized Clinical Trials.

ABSTRACT: Dual antiplatelet therapy (DAPT) is recommended after percutaneous coronary intervention (PCI), though the optimal duration is unclear. DAPT reduces stent thrombosis, repeat myocardial infarction, and cardiovascular death, though at the cost of increased bleeding events. Currently, both European and American guidelines recommend a 6-month duration of DAPT following PCI with drug-eluting stents (DES) for stable coronary disease and a 12-month regimen following PCI for acute coronary syndrome. Recent randomized clinical trials (RCTs) suggest a shorter duration of DAPT may be acceptable. PubMed, EMBASE, and Cochrane databases were queried from inception to June 2025 to identify RCTs comparing short ( ≤ 3 months) with traditional durations of DAPT following PCI with DES and reporting outcomes

SUBMITTER: Fretz T 

PROVIDER: S-EPMC12617329 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature